Bizily Scott, the Chief Legal Officer at 4D Molecular Therapeutics, Inc., has recently made significant stock transactions, as detailed in a filing with the SEC. This activity is important as it reflects both personal investment strategies and broader trends within the life sciences sector.
Background
4D Molecular Therapeutics, Inc. operates in the biological products industry, focusing on innovative therapies. The company is based in Emeryville, California, and is listed under the SEC file number 001-39782. Bizily Scott has been actively involved in the company, as evidenced by multiple recent filings.
What the Filing Says
The SEC filing dated October 20, 2026, reveals that Scott executed two transactions on October 16, 2026. In one transaction, he acquired 1,635 shares of common stock at a price of $4.14 per share. In another, he disposed of 1,635 shares at a price of $12.84 per share. Following these transactions, Scott holds a total of 10,252 shares directly.
Impact
Scott's transactions may have implications for the company's governance and investor relations. As a key officer, his stock activity can influence perceptions among investors and stakeholders. The filing also indicates that Scott has a structured approach to managing his stock, adhering to a 10b5-1 trading plan established earlier this year.
What's Next
Details were not available in the SEC filing regarding any upcoming actions or future plans following these transactions.